Privi Speciality Chemicals Limited announces an acquisition

The exact share exchange ratio cannot be determined from the cited Scheme notice extract. The extract only identifies Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited as the transferor companies merging into Privi Speciality Chemicals Limited, with an appointed date of 1 October 2025; it does not reproduce the consideration or share-entitlement clause. ^[1]

Accordingly, the extract also does not disclose the transferor entity’s valuation, its latest audited book value, or the resulting premium/discount to book value. No defensible comparison can therefore be calculated without the Scheme’s valuation report or the relevant “share exchange ratio/consideration” and audited financial statements sections.

The available Scheme notice does not report the pro-forma debt, equity, profit after tax, or post-amalgamation share count, so the projected change in Privi Speciality Chemicals’ consolidated debt-to-equity ratio and EPS cannot be quantified reliably from the cited material.

The scheme proposes amalgamating Privi Fine Sciences and Privi Biotechnologies into Privi Speciality Chemicals, with an appointed date of 1 October 2025. ^[1]

The required calculation would be:

• Pro-forma consolidated debt-to-equity ratio = post-amalgamation total debt ÷ post-amalgamation total equity.
• Pro-forma EPS = post-amalgamation consolidated PAT ÷ post-scheme weighted-average equity shares.

Accordingly, the direction of impact—whether leverage declines or rises, and whether EPS is accretive or dilutive—cannot be established without the pro-forma balance sheet, consolidated PAT and post-scheme share-count figures. The exchange-observation material indicates that the post-scheme balance sheet and relevant financial information are required disclosures, but it does not provide those figures itself. ^[2]

The Scheme was not effective merely because the NCLT-convened shareholder meeting was held. The remaining gates are the NCLT’s final sanction/order, followed by filing the certified order and requisite e-forms with the Registrar of Companies (ROC). The Scheme would then become effective in accordance with its terms, after which the company can determine and announce the record date. The disclosed target was completion by December 2026. ^[3]

Remaining milestones

• Shareholder approval: The NCLT-directed meeting was scheduled for 27 October 2026 to consider the amalgamation of Privi Fine Sciences and Privi Biotechnologies into Privi Speciality Chemicals. ^[4]
• Final NCLT order: The shareholder meeting does not itself sanction the Scheme; the final NCLT approval/order remains a necessary step.
• ROC filing: The sanctioned Scheme/order and the prescribed e-forms must be filed with the ROC. The company’s annual-report resolution authorises filing the necessary ROC e-forms to give effect to the resolution. ^[3]
• Effectiveness and implementation: Effectiveness would follow the applicable order/ROC-filing requirements, after which the company would proceed with implementation actions, including fixing the record date.

Record-date timing

Management’s indicated timeline was effectively after completion of the approval and ROC-filing process, with the overall merger expected to be completed by December 2026. ^[3] The cited disclosure does not provide a specific record-date day or a precise number of days after the ROC filing; therefore, the record date should be treated as a post-effectiveness step rather than a date already fixed.